Nasdaq:US$13.50 (+0.55) | HKEX:HK$21.80 (+0.60) | AIM:£2.26 (+0.09)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors